Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yamashita Health Care Holdings (TSE:9265) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Feb. 2026) net income data. The Revenue data used here is four times the quarterly (Feb. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Yamashita Health Care Holdings ROE % Related Terms
Yamashita Health Care Holdings ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Yamashita Health Care Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yamashita Health Care Holdings ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Yamashita Health Care Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Yamashita Health Care Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Yamashita Health Care Holdings (TSE:9265) has a ROE % of 13.80% as of Feb. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Yamashita Health Care Holdings and its competitors. This is 96% above median its historical median of 7.03. Over the past decade, Yamashita Health Care Holdings' ROE % has ranged from 2.28 to 9.35. According to the industry distribution chart, Yamashita Health Care Holdings ranks #56 out of 113 companies in the Medical Distribution industry, placing it in the top 49.6%.
Is Yamashita Health Care Holdings' ROE % too high?
Yamashita Health Care Holdings' current ROE % of 13.80% is 96% above median its 10-year median of 7.03. Over the past 10 years, this metric has ranged from a low of 2.28 to a high of 9.35. The Medical Distribution industry median ROE % is 7.15. Yamashita Health Care Holdings' value of 13.80% is 93% above this industry median. Based on the distribution chart, Yamashita Health Care Holdings ranks #56 out of 113 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Yamashita Health Care Holdings has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yamashita Health Care Holdings' ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Yamashita Health Care Holdings ranks #56 out of 113 companies for ROE %. This puts Yamashita Health Care Holdings in the upper half of its industry. The industry median ROE % is 7.15. Yamashita Health Care Holdings' value of 13.80% is 93% above this benchmark. Historically, Yamashita Health Care Holdings' own ROE % has ranged from 2.28 to 9.35 over the past decade. While the company's 10-year median is 7.03 vs. the industry median of 7.15, Yamashita Health Care Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.15, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yamashita Health Care Holdings's current ROE % of 13.80% is 93% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Yamashita Health Care Holdings and its competitors. For the Medical Distribution industry, the median ROE % is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yamashita Health Care Holdings's current ROE % is 13.80%, which is 96% above median its own 10-year median of 7.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yamashita Health Care Holdings stock overvalued right now?
Based on GuruFocus' analysis, Yamashita Health Care Holdings (TSE:9265) is currently considered Modestly Overvalued. The stock's GF Value™ is 円2,955.01, compared to a current price of 円3,400.00 — trading 15.1% above its estimated fair value. The current ROE % is 13.80%, which is 96% above median its 10-year median of 7.03 and 93% above the Medical Distribution industry median of 7.15. Yamashita Health Care Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Yamashita Health Care Holdings (TSE:9265), the current ROE % is 13.80% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yamashita Health Care Holdings (TSE:9265) Overvalued in 2026?
Based on GuruFocus' analysis, Yamashita Health Care Holdings stock appears to be overvalued.
The current stock price of 円3,400.00 is trading 15.1% above its estimated GF Value™ of 円2,955.01.
GuruFocus considers Yamashita Health Care Holdings to be Modestly Overvalued.
Key valuation signals for TSE:9265:
ROE %: 13.80% (96% above median its 10-year median of 7.03)
GF Value™: 円2,955.01 vs. price of 円3,400.00 (15.1% above fair value)
Industry Position: 93% above the Medical Distribution median (#56 of 113)
No single metric tells the full story. See the TSE:9265 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yamashita Health Care Holdings Inc is a Japan-based medical equipment wholesale company that sells medical equipment for medical institutions within the Kyushu area. The company is also engaged in the manufacture, sale, leasing, and rental of optical instruments, physicochemical instruments, analytical instruments, measuring instruments, health equipment, exercise equipment, nursing care equipment, animal medical equipment, and veterinary drugs.
64GF Score
Get the complete analysis for TSE:9265
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9265 has been successfully added to your 
